In partnership with the iPSC Neurodegenerative Disease Initiative, a project from the Center for Alzheimer's and Related Dementias (NIH), and with support from the Chan Zuckerberg Initiative, and Aligning Science Across Parkinson's (ASAP), The Jackson Laboratory now offers a catalog of human induced pluripotent stem cells (iPSCs) for Alzheimer's and Related Dementias (ADRDs), ALS, and other neurodegenerative disorders. Our human iPSCs are designed to meet the growing demand for precision disease modeling and functional studies.
Our offerings include:
Whether you're exploring ADRD pathology or optimizing drug discovery workflows, our well-characterized iPSC models deliver reproducibility and scalability for your research.
Each iPSC line in our collection undergoes rigorous quality control, ensuring reliable performance and consistency across experiments. These models are powerful tools for uncovering disease mechanisms and accelerating the development of new therapies.
We have selected more than 100 ADRD-associated variants across 73 genes through automated identification and input from leading geneticists. CRISPR-Cas technology was employed to generate heterozygous and homozygous genotypes of these single nucleotide variants (SNVs) in the KOLF2.1J cell line, along with mutation-corrected isogenic “revertant” controls for each mutation. When paired together, these sets offer a broad, quality-controlled toolbox of ADRD cell lines along with genetically-matched controls for highly efficient screening and reproducible results. For more details on the selection of variants, click HERE.
This innovative catalog has been made possible with funding from the Chan Zuckerberg Initiative, Aligning Science Across Parkinson's (ASAP), and our cell development partner the National Institute of Health.
